Literature DB >> 31578205

The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib.

Jennifer M O'Sullivan1,2,3, Angela Hamblin4,5, Christina Yap6,7, Sonia Fox6, Rebecca Boucher6, Anesh Panchal6, Samah Alimam1, Helene Dreau4, Kieran Howard4, Pauline Ware4, Nicholas C P Cross8, Mary Frances McMullin9, Claire N Harrison1, Adam J Mead2,3,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31578205      PMCID： PMC6917505          DOI： 10.1182/blood.2019001861

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  21 in total

1.  Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome.

Authors:  Julia Asp; Björn Andréasson; Ulrika Hansson; Carina Wasslavik; Johanna Abelsson; Peter Johansson; Lars Palmqvist
Journal:  Haematologica       Date:  2016-01-14       Impact factor: 9.941

2.  Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.

Authors:  Carla Al Assaf; Florence Van Obbergh; Johan Billiet; Els Lierman; Timothy Devos; Carlos Graux; Anne-Sophie Hervent; Jan Emmerechts; Thomas Tousseyn; Pascale De Paepe; Petros Papadopoulos; Lucienne Michaux; Peter Vandenberghe
Journal:  Haematologica       Date:  2015-05-01       Impact factor: 9.941

3.  Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.

Authors:  Alicia Senín; Concepción Fernández-Rodríguez; Beatriz Bellosillo; Laura Camacho; Raquel Longarón; Anna Angona; Carles Besses; Alberto Álvarez-Larrán
Journal:  Ann Hematol       Date:  2017-11-27       Impact factor: 3.673

4.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

5.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors:  Alessandro M Vannucchi; Jean Jacques Kiladjian; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Ruben Mesa; Shui He; Mark M Jones; William Garrett; Jingjin Li; Ulrich Pirron; Dany Habr; Srdan Verstovsek
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

6.  Targeted deep sequencing in polycythemia vera and essential thrombocythemia.

Authors:  Ayalew Tefferi; Terra L Lasho; Paola Guglielmelli; Christy M Finke; Giada Rotunno; Yoseph Elala; Annalisa Pacilli; Curtis A Hanson; Alessandro Pancrazzi; Rhett P Ketterling; Carmela Mannarelli; Daniela Barraco; Tiziana Fanelli; Animesh Pardanani; Naseema Gangat; Alessandro M Vannucchi
Journal:  Blood Adv       Date:  2016-11-22

7.  Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.

Authors:  J Broséus; T Alpermann; M Wulfert; L Florensa Brichs; S Jeromin; E Lippert; M Rozman; F Lifermann; V Grossmann; T Haferlach; U Germing; E Luño; F Girodon; S Schnittger
Journal:  Leukemia       Date:  2013-04-18       Impact factor: 11.528

8.  Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.

Authors:  Claire N Harrison; Adam J Mead; Anesh Panchal; Sonia Fox; Christina Yap; Emmanouela Gbandi; Aimee Houlton; Samah Alimam; Joanne Ewing; Marion Wood; Frederick Chen; Jason Coppell; Nicki Panoskaltsis; Steven Knapper; Sahra Ali; Angela Hamblin; Robyn Scherber; Amylou C Dueck; Nicholas C P Cross; Ruben Mesa; Mary Frances McMullin
Journal:  Blood       Date:  2017-08-09       Impact factor: 22.113

9.  Effect of mutation order on myeloproliferative neoplasms.

Authors:  Christina A Ortmann; David G Kent; Jyoti Nangalia; Yvonne Silber; David C Wedge; Jacob Grinfeld; E Joanna Baxter; Charles E Massie; Elli Papaemmanuil; Suraj Menon; Anna L Godfrey; Danai Dimitropoulou; Paola Guglielmelli; Beatriz Bellosillo; Carles Besses; Konstanze Döhner; Claire N Harrison; George S Vassiliou; Alessandro Vannucchi; Peter J Campbell; Anthony R Green
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

10.  JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Authors:  Elisa Rumi; Daniela Pietra; Virginia Ferretti; Thorsten Klampfl; Ashot S Harutyunyan; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Chiara Elena; Ilaria C Casetti; Chiara Milanesi; Emanuela Sant'antonio; Marta Bellini; Elena Fugazza; Maria C Renna; Emanuela Boveri; Cesare Astori; Cristiana Pascutto; Robert Kralovics; Mario Cazzola
Journal:  Blood       Date:  2013-12-23       Impact factor: 22.113
View more
  3 in total

1.  Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms.

Authors:  Graeme Greenfield; Suzanne McPherson; James Smith; Adam Mead; Claire Harrison; Ken Mills; Mary Frances McMullin
Journal:  Cancers (Basel)       Date:  2020-09-18       Impact factor: 6.639

Review 2.  Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses.

Authors:  Vibe Skov
Journal:  Cancers (Basel)       Date:  2020-08-06       Impact factor: 6.639

3.  Identification of Potential Key Genes and Regulatory Markers in Essential Thrombocythemia Through Integrated Bioinformatics Analysis and Clinical Validation.

Authors:  Jie Wang; Yun Wu; Md Nazim Uddin; Rong Chen; Jian-Ping Hao
Journal:  Pharmgenomics Pers Med       Date:  2021-07-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.